|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.17/-1.70
|
企业价值
17.99M
|
资产负债 |
每股账面净值
5.53
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/12 07:07 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction,the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders. |